New Report Reveals 40% of Men Over 45 Have Low Testosterone - Most Don't Know It

HeydayMD's "State of Men's Hormone Health 2026" Finds Men's Telehealth Lags Women's by a Decade as Pentagon Mandates Testosterone Screening for Troops

NEW YORK, July 22, 2026 - A new report from HeydayMD, a men's telehealth platform, finds that up to 40% of men over 45 have clinically low testosterone yet remain undiagnosed - a gap that persists even as the Pentagon rolls out mandatory testosterone screening for service members and federal officials push to widen access to testosterone therapy.

The "State of Men's Hormone Health 2026" report (heydaymd.com/state-of-mens-hormone-health-2026), published this month, examines why men's digital health investment trails women's by an estimated 5 to 10 years and identifies at-home diagnostics as the access breakthrough changing who gets tested.

Key Findings:
* 40% of men over 45 have clinically low testosterone but have never been tested
* The average man waits 2-3 years between first symptoms and getting tested
* 73% of men say they would test their hormones at home if the process were easy
* 70% of HeydayMD patients cite "no lab visit required" as their primary reason for at-home testing
* At-home microsampling shows 98.7% correlation with traditional venipuncture for testosterone
* The U.S. testosterone therapy market is projected to reach $1.2 billion by 2027

Pentagon Screening Mandate Highlights Civilian Gap

The report arrives days after Defense Secretary Pete Hegseth announced annual testosterone screening for all active-duty service members aged 30 and older. The policy, paired with the Trump administration's push to loosen testosterone prescribing rules, has put men's hormone health at the center of a national conversation.

"If the military considers testosterone important enough to screen routinely, the question becomes: why doesn't civilian primary care?" said Jordan Hayes, Media Director at Heyday Health. "The answer is access. Most men can't take a morning off work for a fasting blood draw, wait a week for results, then schedule another appointment to discuss them. At-home testing removes every one of those barriers."

The GLP-1 and Testosterone Connection

The report also highlights a growing clinical intersection: men taking GLP-1 medications like semaglutide for weight loss often need concurrent hormone monitoring. Obesity suppresses testosterone by 30-50%, and rapid weight loss can temporarily worsen that suppression.

"Men on GLP-1 therapy need hormone monitoring - full stop," Hayes said. "Platforms that manage both weight loss and testosterone under one clinical team provide safer, more effective care than bouncing between three different providers."

Men's Digital Health: 5-10 Years Behind

While women's digital health companies have attracted over $3B in venture funding since 2020, the men's health landscape remains fragmented. The report concludes that integrated platforms combining at-home diagnostics, physician-supervised treatment, and longitudinal monitoring will define the next era of men's health.

HEYDAYMD LLC
1209 MOUNTAIN ROAD PL NE STE N ALBUQUERQUE, NM 8711
Jordan Hayes, Media Director
Heyday Health
team@heydaymd.com
heydaymd.com

About HeydayMD

HeydayMD (heydaymd.com) is a men's telehealth platform offering physician-supervised TRT, GLP-1 weight management, and comprehensive health screenings. The platform ships at-home lab kits directly to patients, provides results within 48 hours, and connects patients with licensed providers in all 50 states. HeydayMD requires full hormone panels (40+ biomarkers) before any prescription and mandates 90-day follow-up labs.

This release was published on openPR.